- In February the Company announced that the European Patent Office (EPO) has granted the Company’s European patent application covering pudafensine for the treatment of Female Sexual Dysfunction (FSD)
Business highlights after this reporting period
- In April the Company announced that the company has decided to focus fully on its most promising drug candidate, pudafensine, which is being developed for both vulvodynia and organic erectile dysfunction (ED). As part of this prioritization, the Company will discontinue further development of IP2018
- In April the Company announced good progress in patient enrolment in its Phase IIa clinical proof-of-concept study evaluating pudafensine in women suffering from the genital pain condition, vulvodynia
Financial Highlights
| First Quarter (2026-01-01 – 2026-03-31) |
| Net revenue were KDKK 0 (0) |
| Operating loss, EBIT was KDKK -11,432 (-2,653) |
| Earnings per share before and after dilution was DKK -0.17 (-0.05) |
| Cash: KDKK 19,803 (26,245) |
| Solidity: 68% (88%) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/